Home > Reviews > Thymosin Alpha-1 Review
Thymosin Alpha-1 Review 2025: Research Grade Analysis
Last Updated: February 2025 | By CellForce Labs Research Team | Contains affiliate links
Thymosin Alpha-1 Quick Summary
Thymosin Alpha-1 (TA1) is a 28-amino acid peptide naturally produced by the thymus gland that plays a critical role in immune system development and function. It is approved as a pharmaceutical product (Zadaxin) in over 30 countries for hepatitis B/C treatment and as an immune adjuvant. TA1 is one of the most clinically validated peptides in research, with applications spanning infectious disease, cancer immunotherapy, immune deficiency, and vaccine enhancement.
Disclaimer: CellForgeLabs.com provides information for research purposes only. Products linked are for laboratory research only, not for human consumption. This page contains affiliate links.
Quick Navigation
What is Thymosin Alpha-1?
Thymosin Alpha-1 is a 28-amino acid peptide first isolated from thymosin fraction 5, a preparation derived from bovine thymus glands, by Allan Goldstein at George Washington University in the 1970s. The thymus gland is the master regulator of immune system development, and TA1 is one of its key signaling molecules. It is essential for T-cell maturation, dendritic cell function, and the coordination of innate and adaptive immune responses. The synthetic version (thymalfasin, brand name Zadaxin) has been approved as a pharmaceutical in over 30 countries, primarily in Asia, for treatment of chronic hepatitis B and C, and as an immune adjuvant. This extensive regulatory approval provides one of the strongest clinical evidence bases of any research peptide.
| Category | Immune Modulation |
| Also Known As | TA1, Thymalfasin, Zadaxin |
| Research Status | Approved in 30+ countries |
| Key Function | Thymic peptide for immune system regulation |
| Half-Life | ~2 hours |
Research Benefits of Thymosin Alpha-1
- Immune System Enhancement: Promotes T-cell maturation and activation, enhancing adaptive immune responses.
- Dendritic Cell Activation: Stimulates dendritic cells to better present antigens, improving immune surveillance.
- Hepatitis Treatment: Approved in 30+ countries for chronic hepatitis B and C based on clinical trial evidence.
- Cancer Immunotherapy: Research shows enhanced anti-tumor immune responses when used as an adjuvant to chemotherapy.
- Vaccine Enhancement: Studies demonstrate improved vaccine response rates, particularly in immunocompromised populations.
- Anti-Inflammatory: Modulates inflammatory cytokine balance, reducing excessive inflammation while maintaining pathogen defense.
Mechanism of Action
Thymosin Alpha-1 acts primarily through Toll-like receptors (TLR2 and TLR9) on dendritic cells and other antigen-presenting cells. This activates intracellular signaling cascades (MyD88, NF-kB, IRF7) that enhance antigen presentation, cytokine production, and T-cell priming. TA1 promotes the differentiation of immature T-cells into mature, functional CD4+ and CD8+ effector cells. It also modulates the balance between pro-inflammatory and anti-inflammatory cytokines, enhancing immune defense while preventing excessive inflammatory damage. Additionally, TA1 supports natural killer cell activity and antibody production.
Research Protocols
| Parameter | Research Data |
|---|---|
| Research Dose | 1.6mg (standard clinical dose) |
| Administration | Subcutaneous injection |
| Frequency | 2-3 times per week or daily |
| Research Duration | 6-12 months in clinical studies |
| Half-Life | ~2 hours |
| Storage | Refrigerated at 2-8°C |
Visit our Reconstitution Calculator for dosing calculations.
Side Effects & Safety Profile
Thymosin Alpha-1 has an excellent safety profile established through decades of clinical use across 30+ countries. Adverse effects are rare and mild, consisting primarily of injection site reactions and occasional fatigue. Clinical trials involving thousands of patients have confirmed its tolerability, including in immunocompromised populations. No significant drug interactions have been identified. Its safety record as a regulated pharmaceutical adds confidence for research applications.
Where to Buy Thymosin Alpha-1
| Vendor | Price | Testing | Rating | Link |
|---|---|---|---|---|
| Swiss Chems | $54.95 (5mg) | 3rd-party HPLC + MS | 4.8/5 | Buy → |
| Peptide Sciences | $59.99 (5mg) | 3rd-party HPLC | 4.7/5 | Buy → |
| Amino Asylum | $44.99 (5mg) | In-house | 4.3/5 | Buy → |
Source Verified Thymosin Alpha-1
Third-party tested with HPLC and mass spectrometry verification.
Related Research
Frequently Asked Questions
What is Thymosin Alpha-1 used for?
TA1 is researched for immune enhancement, hepatitis treatment (approved in 30+ countries), cancer immunotherapy adjuvant therapy, vaccine response improvement, and immune deficiency conditions. It is one of the most clinically validated peptides available.
Is Thymosin Alpha-1 approved as a medication?
Yes, TA1 (brand name Zadaxin, generic thymalfasin) is approved as a pharmaceutical product in over 30 countries, primarily for chronic hepatitis B and C treatment and as an immune adjuvant. This provides extensive clinical safety and efficacy data.
Disclosure: CellForgeLabs.com is an affiliate site. We earn commissions from qualifying purchases. All products referenced are for laboratory research purposes only.